Impact of Perforin 1 A91V germ line background in patients with aggressive B-NHL treated with R-CHOP.

Blood Adv · 2026 · PMC12915228 · PMID 41358738

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

a favorable trendno p-value reported

A favorable trend for PRF1 A91V carriers treated with CHOP or cyclophosphamide, doxorubicin, vincristine, etoposide and prednisone or prednisolone 14/21 was observed, with a 36-month EFS of 68% vs 50% ( P = .058) and significantly higher OS at 87% vs 60% ( P = .030; Figure 2 ).

also in 993 other papers

highly significantno p-value reported

Patients with PRF1 wild type, representing the majority (87%), however, benefited highly significant from addition of rituximab.

also in 83,176 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.